Breast Cancer Screening Tests Market Overview
Breast cancer is one of the most frequent cancers in women worldwide, and it is a leading cause of death. As a result, many disorders require early identification. Due to sophisticated lifestyles, breast cancer is more common in developed countries; nevertheless, the rate of occurrence is predicted to climb in emerging countries. The global Breast Cancer Screening Tests market is projected to boost at a significant rate in the forthcoming years. According to World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer.
Women's education and living standards have improved, resulting in later first pregnancies and a shorter lactation period, which has resulted in fluctuating hormone levels and a higher risk of breast cancer. Breast cancer risk rises as people get older. As a result, an increase in the elderly population is a major contributor to the growth in breast cancer incidence. The market is being driven by the rising incidence of breast cancer, growing awareness about breast cancer screening tests, government initiatives for breast cancer screening programs, technical advancements in breast imaging technologies, and the government's implementation of national-level programs for early diagnosis.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Diagnostic Test Type, End-User, and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | A&G Pharmaceutical, Inc., Biocrates Life Sciences AG, Metabolomic Technologies, Inc., Myriad Genetics, Siemens Healthcare Diagnostics, Inc., OncoCyte Corporation, POC Medical Systems, Inc., Hologic, Inc., Provista Diagnostics, Inc., BioTime, Inc. |
Covid-19 Impact on Breast Cancer Screening Tests Market
In addition, the current Breast Cancer Screening Tests Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Breast Cancer Screening Tests Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Breast Cancer Screening Tests Market Segment Overview
Based on diagnostic test type, the Imaging test is one of the most important segments in the global breast cancer screening tests market. The imaging test is the most commonly used test for the screening of breast cancer. This segment is divided into mammography, MRI screening test, molecular breast imaging test, PET scan, and ultrasound. Mammography is the most common test used for the detection of breast cancer. Mammography is the most popular breast cancer screening test in most developed nations since it is included in the breast screening program. By the end-user, the diagnostic center is a major segment of the market. The expansion of the diagnostic centers segment is aided by national breast cancer screening programs and increased awareness of breast cancer genetic transmission.
Breast Cancer Screening Tests Market, By Diagnostic Test Type
- Blood Marker Tests
- Imaging Test
- Mammography
- MRI screening test
- Molecular Breast Imaging Test
- PET scan
- Ultrasound
- Genetic Test
- Fluorescence In Situ Hybridization
- HER gene test
- Immunohistochemistry Test
Breast Cancer Screening Tests Market, By End-User
· Hospitals
· Diagnostic Centers
· Cancer Institutes
· Research Laboratories
Breast Cancer Screening Tests Market Regional Overview
Region-Wise, North America held the largest share in the Breast Cancer Screening Tests market. This is because 70% of women in the U.S. undergo mammography. Furthermore, Europe is another major region for the market. Germany is expected to dominate the market in Europe This is due to advanced health care infrastructure and government-supported screening programs. Again, the market in the Asia Pacific is projected to rise at a considerable rate in the coming years. Availability of screening services in private health care and diagnostic centers is predicted to drive the market in developing countries such as India.
Breast Cancer Screening Tests Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Breast Cancer Screening Tests Market, Key Players
· A&G Pharmaceutical, Inc.
· Biocrates Life Sciences AG
· Metabolomic Technologies, Inc.
· Myriad Genetics
· Siemens Healthcare Diagnostics, Inc.
· OncoCyte Corporation
· POC Medical Systems, Inc.
· Hologic, Inc.
· Provista Diagnostics, Inc.
· BioTime, Inc.
Frequently Asked Questions (FAQ) :
Q1. What are the driving factors for the Breast Cancer Screening Tests market?
The market is being driven by the rising incidence of breast cancer, growing awareness about breast cancer screening tests, government initiatives for breast cancer screening programs, technical advancements in breast imaging technologies, and the government's implementation of national-level programs for early diagnosis.
Q2. Which Segments are covered in the Breast Cancer Screening Tests Market report?
Diagnostic Test Type, End-User, and Region. these segments are covered in the Breast Cancer Screening Tests Market report.
Q3. Which segment is projected to hold the largest share in the Breast Cancer Screening Tests Market?
The imaging test segment is projected to hold the largest share in the Breast Cancer Screening Tests Market.
Q4. Which region holds the largest share in the Breast Cancer Screening Tests market?
North America held the largest share in the global Breast Cancer Screening Tests Market
Q5. Which are the prominent players in the Breast Cancer Screening Tests Market?
A&G Pharmaceutical, Inc., Biocrates Life Sciences AG, Metabolomic Technologies, Inc., Myriad Genetics, Siemens Healthcare Diagnostics, Inc., OncoCyte Corporation, POC Medical Systems, Inc., Hologic, Inc., Provista Diagnostics, Inc., BioTime, Inc. are some key players in the Breast Cancer Screening Tests Market.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
- 5.2.1. Blood Marker Tests
- 5.2.2. Imaging Test
- 5.2.2.1. Mammography
- 5.2.2.2. MRI screening test
- 5.2.2.3. Molecular Breast Imaging Test
- 5.2.2.4. PET scan
- 5.2.2.5. Ultrasound
- 5.2.3. Genetic Test
- 5.2.3.1. Fluorescence In Situ Hybridization
- 5.2.3.2. HER gene test
- 5.2.4. Immunohistochemistry Test
- 5.3. Market Analysis, Insights and Forecast – By End-User
- 5.3.1. Hospitals
- 5.3.2. Diagnostic Centers
- 5.3.3. Cancer Institutes
- 5.3.4. Research Laboratories
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
- 6.2.1. Blood Marker Tests
- 6.2.2. Imaging Test
- 6.2.2.1. Mammography
- 6.2.2.2. MRI screening test
- 6.2.2.3. Molecular Breast Imaging Test
- 6.2.2.4. PET scan
- 6.2.2.5. Ultrasound
- 6.2.3. Genetic Test
- 6.2.3.1. Fluorescence In Situ Hybridization
- 6.2.3.2. HER gene test
- 6.2.4. Immunohistochemistry Test
- 6.3. Market Analysis, Insights and Forecast – By End-User
- 6.3.1. Hospitals
- 6.3.2. Diagnostic Centers
- 6.3.3. Cancer Institutes
- 6.3.4. Research Laboratories
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
- 7.2.1. Blood Marker Tests
- 7.2.2. Imaging Test
- 7.2.2.1. Mammography
- 7.2.2.2. MRI screening test
- 7.2.2.3. Molecular Breast Imaging Test
- 7.2.2.4. PET scan
- 7.2.2.5. Ultrasound
- 7.2.3. Genetic Test
- 7.2.3.1. Fluorescence In Situ Hybridization
- 7.2.3.2. HER gene test
- 7.2.4. Immunohistochemistry Test
- 7.3. Market Analysis, Insights and Forecast – By End-User
- 7.3.1. Hospitals
- 7.3.2. Diagnostic Centers
- 7.3.3. Cancer Institutes
- 7.3.4. Research Laboratories
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
- 8.2.1. Blood Marker Tests
- 8.2.2. Imaging Test
- 8.2.2.1. Mammography
- 8.2.2.2. MRI screening test
- 8.2.2.3. Molecular Breast Imaging Test
- 8.2.2.4. PET scan
- 8.2.2.5. Ultrasound
- 8.2.3. Genetic Test
- 8.2.3.1. Fluorescence In Situ Hybridization
- 8.2.3.2. HER gene test
- 8.2.4. Immunohistochemistry Test
- 8.3. Market Analysis, Insights and Forecast – By End-User
- 8.3.1. Hospitals
- 8.3.2. Diagnostic Centers
- 8.3.3. Cancer Institutes
- 8.3.4. Research Laboratories
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
- 9.2.1. Blood Marker Tests
- 9.2.2. Imaging Test
- 9.2.2.1. Mammography
- 9.2.2.2. MRI screening test
- 9.2.2.3. Molecular Breast Imaging Test
- 9.2.2.4. PET scan
- 9.2.2.5. Ultrasound
- 9.2.3. Genetic Test
- 9.2.3.1. Fluorescence In Situ Hybridization
- 9.2.3.2. HER gene test
- 9.2.4. Immunohistochemistry Test
- 9.3. Market Analysis, Insights and Forecast – By End-User
- 9.3.1. Hospitals
- 9.3.2. Diagnostic Centers
- 9.3.3. Cancer Institutes
- 9.3.4. Research Laboratories
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. A&G Pharmaceutical, Inc.
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Biocrates Life Sciences AG
- 10.6. Metabolomic Technologies, Inc.
- 10.7. Myriad Genetics
- 10.8. Siemens Healthcare Diagnostics, Inc.
- 10.9. OncoCyte Corporation
- 10.10. POC Medical Systems, Inc.
- 10.11. Hologic, Inc.
- 10.12. Provista Diagnostics, Inc.
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
